Deprettere A R, Van Acker K J, Du Caju M V
Eur J Pediatr. 1987 Mar;146(2):189-91. doi: 10.1007/BF02343232.
The influence of the dopamine receptor blocking agent domperidone on prolactin and TSH secretion was studied in 16 infants, aged 10-360 days, who were treated for gastroesophageal reflux. The pretreatment serum prolactin levels were not statistically different from the levels in age-matched controls and showed the well-known inverse relationship with age. During treatment with domperidone a significant increase in prolactin level was observed on days 1, 4 and 21-28, the mean values on these three days not being statistically different. No correlation could be found between the serum prolactin levels and the corresponding plasma domperidone levels. One infant of this series and three not included in this series developed reversible breast hypertrophy with galactorrhoea in three of them: in none of them was the prolactin level, corrected for age, above 1 SD of the mean. All had received relatively high doses of domperidone. In 13 patients domperidone did not influence TSH secretion.
对16名年龄在10至360天、因胃食管反流接受治疗的婴儿,研究了多巴胺受体阻滞剂多潘立酮对催乳素和促甲状腺激素分泌的影响。治疗前血清催乳素水平与年龄匹配的对照组相比无统计学差异,且呈现出与年龄众所周知的负相关关系。在多潘立酮治疗期间,第1天、第4天以及第21至28天观察到催乳素水平显著升高,这三天的平均值无统计学差异。血清催乳素水平与相应血浆多潘立酮水平之间未发现相关性。该系列中有1名婴儿以及未纳入该系列的3名婴儿出现了可逆性乳腺肥大,其中3名伴有溢乳:校正年龄后,他们的催乳素水平均未高于均值的1个标准差。他们均接受了相对高剂量的多潘立酮。13名患者中,多潘立酮未影响促甲状腺激素分泌。